Insulin-like growth factor -1 (IGF-1) derived neuropeptides, a novel strategy for the development of pharmaceuticals for managing ischemic brain injury

CNS Neuroscience and Therapeutics

Volumn 17, Issue 4, 2011, Pages 250-255

  Guan, Jian ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Endogenous neuropeptides; G2 mPE; GPE; Ischemic brain injury in rats

Indexed keywords

GLUCOSE; GLYCINE 2 METHYL PROLINE GLUTAMATE; GLYCINE PROLINE GLUTAMATE; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; SOMATOMEDIN C; TRIPEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; APOPTOSIS; ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN ISCHEMIA; CORE TEMPERATURE; DRUG MECHANISM; DRUG STABILITY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROTEIN INDUCTION; REPERFUSION; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN INJURIES; BRAIN ISCHEMIA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS;

EID: 79960378802     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00128.x     Document Type: Review

References (52)

1. Beilharz EJ, Bassett NS, Sirimanne ES, Williams CE, Gluckman PD. Insulin-like growth factor II is induced during wound repair following hypoxic-ischemic injury in the developing rat brain. Mol Brain Res 1995;29:81-91.
2. Gluckman PD, Ambler GR. Therapeutic use of insulin-like growth factor I: Lessons from in vivo animal studies. Acta Paediatr Suppl 1992;383:134-136.
3. Lee WH, Wang GM, Seaman LB, Vannucci SJ. Coordinate IGF-I and IGFBP5 gene expression in perinatal rat brain after hypoxia-ischemia. J Cerebral Blood Flow Metab 1996;16:227-236.
4. Yamaguchi F, Itano T, Miyamoto O, et al. Increase of extracellular insulin-like growth factor I (IGF-I) concentration following electrolytical lesion in rat hippocampus. Neurosci Lett 1991;128:273-276.
5. Scheepens A, Williams CE, Breier BH, Guan J, Gluckman PD. A role for the somatotropic axis in neural development, injury, and disease. J Pediatr Endocrinol Metab 2000;13(Suppl 6):1483-1491.
6. Guan J, Williams C, Gunning M, Mallard C, Gluckman P. The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats. J Cereb Blood Flow Metab 1993;13:609-616.
7. Johnston BM, Mallard EC, Williams CE, Gluckman PD. Insulin-like growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambs. J Clin Invest 1996;97:300-308.
8. Guan J, Bennet L, George S, et al. Insulin-like growth factor-1 reduces postischemic white matter injury in fetal sheep. J Cereb Blood Flow Metab 2001;21:493-502.
9. Guan J, Miller OT, Waugh KM, McCarthy D, Gluckman PD. Insulin-like growth factor-1 improves somatosensory function and reduces the extent of cortical infarction and ongoing neuronal loss after hypoxia-ischemia in rats. Neuroscience 2001;105:299-306.
10. Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713-731.
11. Liu XF, Fawcett JR, Thorne RG, Frey WH. Noninvasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 2001;308:91-94.
12. Saatman KE, Contreras PC, Smith DH, et al. Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury. Exp Neurol 1997;147:418-427.
13. Sara VR, Carlsson-Sdwirut C, Bergman T, et al. Indentification of Gly-Pre-Glu(GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncted in brain, as a novel neuroaction peptide. Biochem Biophys Res Commun 1989;165:766-771.
14. Nilsson-Hakansson L, Civalero I, Zhang X, et al. Effects of IGF-1, truncated IGF-1, and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain. Neuroreport 1993;4:1111-1114.
15. Yamamoto H, Maake C, Murphy LJ. Enhanced proteolytic activity directed against the N-terminal of IGF-I in diabetic rats. J Endocrinol 1999;162:243-250.
16. Yamamoto H, Murphy LJ. Enzymatic conversion of IGF-I to Des(1-3)IGF-I in rat serum and tissues: A further potential site of growth hormone regulation of IGF-I action. J Endocrinol 1995;146:141-148.
17. Yamamoto H, Murphy LJ. N-terminal truncated insulin-like growth factor-I in human urine. J Clin Endocrinol Metab 1995;80:1179-1183.
18. Bourguignon JP, Gerard A. Role of insulin-like growth factor binding proteins in limitation of IGF-1 degradation into the N-methyl-d-aspartate receptor antagonist GPE: Evidence from gonadotrophin-releasing hormone secretion in vitro at two developmental stages. Brain Res 1999;847:247-252.
19. Bourguignon JP, Gerard A, Alvarez Gonzalez ML, Franchimont P. Acute suppression of gonadotropin-releasing hormone secretion by insulin-like growth factor I and subproducts: An age-dependent endocrine effect. Neuroendocrine 1993;58:525-530.
20. Saura J, Curatolo L, Williams CE, et al. Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro. Neuroreport 1999;10:161-164.
21. Guan J, Waldvogel HJ, Faull RL, Gluckman PD, Williams CE. The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 1999;89:649-659.
22. Guan J, Williams CE, Skinner SJ, Mallard EC, Gluckman PD. The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: Evidence for a role for IGF binding proteins. Endocrinology 1996;137:893-898.
23. Batchelor DC, Lin H, Wen J-Y, et al. Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Anal Biochem 2003;323:156-163.
24. Baker AM, Batchelor DC, Thomas GB, et al. Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat. Neuropeptides 2005;39:81-87.
25. Guan J, Thomas GB, Lin H, et al. Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology 2004;47:892-903.
26. Betz AL, Keep RF, Beer ME, Ren XD. Blood-brain barrier permeability and brain concentration of sodium, potassium, and chloride during focal ischemia. J Cereb Blood Flow Metab 1994;14:29-37.
27. Preston E, Sutherland G, Finsten A. Three openings of the blood-brain barrier produced by forebrain ischemia in the rat. Neurosci Lett 1993;149:75-78.
28. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999;842:92-100.
29. Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001;8:834-846.
30. Shapira S, Mathai S, Zhang R, Guan J. Delayed peripheral administration of the N-terminal tripeptide of IGF-1 (GPE) reduces brain damage following microsphere induced embolic damage in young adult and aged rats. Neurosci Lett 2009;454:53-57.
31. Lees KR. Management of acute stroke. Lancet Neurol 2002;1:41-50.
32. Harris PWR, Brimble MA, Muir VJ, et al. Synthesis of proline-medified analogues of the neuroprotective agent glucyl-l-prolyl-glutamic acid (GPE). Tetrahedorn 2005;61:10018-10035.
33. Bickerdike MJ, Thomas GB, Batchelor DC, et al. NNZ-2566: A Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J Neurol Sci 2009;278:85-90.
34. Zhao X, Liu SJ, Zhang J, et al. Combining insulin-like growth factor derivatives plus caffeinol produces robust neuroprotection after stroke in rats. Stroke 2005;36:129-134.
35. Svedin P, Guan J, Mathai S, et al. Delayed peripheral administration of a GPE analogue induces astrogliosis and angiogenesis and reduces inflammation and brain injury following hypoxia-ischemia in the neonatal rat. Develop Neurosci 2007;29:393-402.
36. Lu XC, Si Y, Williams AJ, et al. NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats. J Cereb Blood Flow Metab 2009;29:1924-1932.
37. Ikeda T, Waldbillig RJ, Puro DG. Truncation of IGF-I yields two mitogens for retinal Muller glial cells. Brain Res 1995;686:87-92.
38. Alonso De Diego SA, Gutierrez-Rodriguez M, Perez de Vega MJ, et al. The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett 2006;16:3396-3400.
39. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999;22:391-397.
40. Blomgren K. Pathological apoptosis in the developing brain. Apoptosis 2007;12:993-1010.
41. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: Structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1:223-236.
42. Kraig RP, Lascola CD, Cagiano A. Glial response to brain ischemia. In: Kettenmann H, Ransom BR, editors. Neuroglia. New York: Oxford University Press, 1995; 964-976.
43. Panickar KS, Norenberg MD. Astrocytes in cerebral ischemic injury: Morphological and general considerations. Glia 2005;50:287-298.
44. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: Cellular and molecular cues to biological function. Trends Neurosci 1997;20:570-577.
45. Maragakis NJ, Rothstein JD. Mechanisms of disease: Astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006;2:679-689.
46. Acker T, Beck H, Plate KH. Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev 2001;108:45-57.
47. Frontczak-Baniewicz M, Walski M. Nonsprouting angiogenesis in neurohypophysis after traumatic injury of the cerebral cortex. Electron-microscopic studies. Neuro Endocrinol Lett 2002;23:396-404.
48. Salhia B, Angelov L, Roncari L, et al. Expression of vascular endothelial growth factor by reactive astrocytes and associated neoangiogenesis. Brain Res 2000;883:87-97.
49. Lopez-Lopez C, LeRoith D, Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci USA 2004;101:9833-9838.
50. Cao Y, Gunn AJ, Bennet L, et al. Insulin-like growth factor (IGF)-1 suppresses oligodendrocyte caspase-3 activation and increases glial proliferation after ischemia in near-term fetal sheep. J Cereb Blood Flow Metab 2003;23:739-747.
51. McNeill H, Williams C, Guan J, et al. Neuronal rescue with transforming growth factor-beta 1 after hypoxic-ischaemic brain injury. Neuroreport 1994;5:901-904.
52. Tanaka K, Fukuuchi Y, Gomi S, et al. Inhibition of nitric oxide synthesis impairs autoregulation of local cerebral blood flow in the rat. Neuroreport 1993;4:267-270.